Transcatheter Heart Valve Replacement and Repair Market Size, Share, Growth, and Industry Analysis, By Type (Transcatheter Aortic Valve Replacement (TAVR),Transcatheter Mitral Valve Repair (TMVR)), By Application (Hospitals,Ambulatory Surgical Centers,Cardiac Catheterization Laboratory), Regional Insights and Forecast to 2035

Transcatheter Heart Valve Replacement and Repair Market Overview

The global Transcatheter Heart Valve Replacement and Repair Market is forecast to expand from USD 15032.64 million in 2026 to USD 17841.75 million in 2027, and is expected to reach USD 70162.33 million by 2035, growing at a CAGR of 18.67% over the forecast period.

The Transcatheter Heart Valve Replacement and Repair Market is expanding rapidly as cardiovascular diseases affect over 523 million people globally, with valvular heart disease impacting more than 100 million patients. In 2023, more than 680,000 transcatheter procedures were performed worldwide, accounting for 58% of all minimally invasive cardiac valve interventions. Aortic valve replacement is the most widely adopted, representing 71% of the transcatheter procedures, while mitral valve repair and replacement together account for 19%. Rising adoption in aging populations, where nearly 17% of the world’s population is over 65 years old, is accelerating global demand for these procedures.

In the USA, the Transcatheter Heart Valve Replacement and Repair Market accounts for nearly 37% of global procedures, with more than 250,000 transcatheter valve interventions performed in 2023. Aortic valve replacements dominate, representing 72% of all procedures, while mitral valve repair and replacement account for 21%. Over 95,000 procedures were performed on patients above 75 years, highlighting strong adoption among the elderly. Nearly 68% of procedures in the USA are conducted in specialized cardiac centers, while 42% of patients were classified as high surgical risk. With heart disease being the leading cause of death for 695,000 Americans annually, demand continues to grow.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key findings

• Key Market Driver: Nearly 71% of procedures globally are aortic valve replacements, driven by an aging population where 17% are over 65 years old.
• Major Market Restraint: Around 38% of patients face limited access due to high treatment costs and inadequate reimbursement policies worldwide.
• Emerging Trends: More than 29% of new procedures in 2023 involved next-generation transcatheter valves with enhanced durability and reduced complications.
• Regional Leadership: North America holds 37% of global procedure volume, followed by Europe at 32% and Asia-Pacific at 25%.
• Competitive Landscape: Top 5 companies control 64% of the global market, with strong investments in valve innovation and clinical trials.
• Market Segmentation: Aortic valve replacement accounts for 71% of procedures, mitral valve 19%, and tricuspid/pulmonary valve 10% collectively.
• Recent Development: Between 2022–2023, nearly 85,000 patients globally were treated with next-generation self-expanding valves offering 20% lower complication rates.

Transcatheter Heart Valve Replacement and Repair Market Latest Trends

The Transcatheter Heart Valve Replacement and Repair Market is witnessing rapid technological advancement and increased procedural adoption. In 2023, more than 680,000 procedures were conducted globally, marking a 22% rise compared to 2020. Self-expanding and balloon-expandable valves dominate, representing 61% and 33% of the global procedures, respectively. Minimally invasive valve-in-valve procedures are also growing, accounting for 12% of total interventions. Europe reported over 210,000 procedures in 2023, with Germany alone performing more than 45,000 transcatheter interventions. Asia-Pacific is becoming a key growth region, with China and India performing nearly 95,000 procedures combined in 2023. Hospitals and cardiac specialty centers accounted for 82% of global procedures. Furthermore, patient preference for minimally invasive procedures is increasing, with surveys showing 67% of patients prefer transcatheter interventions over open-heart surgery due to faster recovery times, lower risks, and improved outcomes. This shift continues to drive Transcatheter Heart Valve Replacement and Repair Market Growth.

How is technological advancement driving the Transcatheter Heart Valve Replacement and Repair Market?

Technological advancements are transforming the Transcatheter Heart Valve Replacement and Repair Market through the development of next-generation valve systems, advanced catheter technologies, and high-resolution imaging platforms. Improvements in self-expanding and balloon-expandable valves, enhanced delivery systems, and real-time procedural imaging have increased procedural precision while reducing complications and recovery times. Continuous innovation in valve durability and minimally invasive techniques is expanding patient eligibility and supporting wider clinical adoption across healthcare systems.

Transcatheter Heart Valve Replacement and Repair Market Dynamics

DRIVER

"Increasing prevalence of cardiovascular and valvular heart diseases"

The major driver of the Transcatheter Heart Valve Replacement and Repair Market is the growing prevalence of cardiovascular and valvular heart diseases. Globally, more than 100 million patients are diagnosed with valvular disorders, with aortic stenosis and mitral regurgitation being the most common. Aortic stenosis affects nearly 13% of the population above 75 years, while mitral regurgitation affects 24 million patients worldwide. In 2023, 72% of all transcatheter procedures addressed aortic stenosis. In the USA alone, more than 95,000 elderly patients underwent transcatheter procedures. Rising incidences, combined with an aging global population, continue to drive market expansion as hospitals prioritize advanced treatment options.

RESTRAINT

"High cost of treatment and limited accessibility"

One of the major restraints for the Transcatheter Heart Valve Replacement and Repair Market is the high cost of treatment and limited accessibility. Around 38% of patients worldwide are unable to afford transcatheter procedures due to high device costs and inadequate reimbursement systems. In emerging economies, 42% of hospitals report limited adoption due to financial constraints. The average cost of a transcatheter heart valve device can be 2 to 3 times higher than surgical alternatives, creating barriers for low- and middle-income patients. Even in developed regions like North America, 29% of patients delay procedures due to affordability concerns.

OPPORTUNITY

"Advancements in next-generation valves and minimally invasive techniques"

A significant opportunity in the Transcatheter Heart Valve Replacement and Repair Market lies in advancements in next-generation valves and minimally invasive techniques. In 2023, more than 85,000 patients worldwide were treated with self-expanding next-generation valves offering 20% lower complication rates and longer durability. Valve-in-valve procedures have grown by 18% in the last three years, reducing the need for repeat surgeries. Asia-Pacific hospitals are adopting new-generation valves rapidly, with 27% of procedures in 2023 using advanced devices. Expanding research into tricuspid and pulmonary valves, currently representing 10% of global demand, also opens growth opportunities, especially in pediatric and congenital cases.

CHALLENGE

"Limited skilled workforce and procedural risks"

One of the main challenges for the Transcatheter Heart Valve Replacement and Repair Market is the shortage of skilled professionals and procedural risks. Globally, only 46% of hospitals offering transcatheter procedures have fully trained specialists. In 2023, complication rates remained at 6.7%, with paravalvular leaks being the most frequent. In developing regions, 31% of hospitals report challenges in training staff and maintaining advanced cath-lab infrastructure. In addition, procedural risks, such as stroke (occurring in 2–3% of patients) and device migration (1.5%), remain major concerns. Addressing these workforce and technical challenges is critical to expanding global adoption of transcatheter interventions.

Why is demand increasing for the Transcatheter Heart Valve Replacement and Repair industry?

Demand is increasing due to the rising prevalence of valvular heart diseases, growing elderly populations, and the preference for minimally invasive treatment options over open-heart surgery. Patients benefit from shorter hospital stays, faster recovery, and lower procedural risks, making transcatheter interventions an attractive treatment choice. Increasing awareness, improved access to specialized cardiac centers, and expanding clinical indications are further driving the adoption of transcatheter heart valve replacement and repair procedures worldwide.

Transcatheter Heart Valve Replacement and Repair Market Segmentation 

The Transcatheter Heart Valve Replacement and Repair Market is segmented by type and application, reflecting the specialized use of procedures across patient populations and healthcare facilities. By type, the market is divided into Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral Valve Repair (TMVR), which together account for more than 90% of all transcatheter interventions globally. By application, the market is segmented into Hospitals, Ambulatory Surgical Centers, and Cardiac Catheterization Laboratories, each playing a vital role in the adoption and execution of minimally invasive cardiac procedures. This segmentation highlights the clinical and infrastructural drivers shaping global adoption rates.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Transcatheter Aortic Valve Replacement (TAVR)

Transcatheter Aortic Valve Replacement (TAVR) is the largest segment of the transcatheter heart valve market, accounting for approximately 71% of all transcatheter interventions worldwide. The procedure has become the preferred treatment option for patients with severe aortic stenosis, particularly elderly and high-risk individuals, due to its minimally invasive approach, shorter recovery period, and lower complication rates compared with conventional open-heart surgery.

Growing clinical evidence, continuous technological advancements in valve design, and expanding eligibility criteria have accelerated TAVR adoption across healthcare systems. Increasing use of valve-in-valve procedures, improvements in procedural safety, and broader availability of specialized cardiac centers continue to strengthen demand for TAVR globally.

Transcatheter Mitral Valve Repair (TMVR)

Transcatheter Mitral Valve Repair (TMVR) represents approximately 19% of the market and continues to gain acceptance as an effective minimally invasive treatment for patients with mitral regurgitation. The procedure is particularly beneficial for elderly patients and those considered unsuitable for conventional surgery, offering reduced hospital stays and faster recovery while improving overall patient outcomes.

Ongoing innovation in catheter-based repair systems, improved valve durability, and expanding clinical experience are supporting wider adoption of TMVR. Increasing prevalence of mitral valve disorders and growing preference for minimally invasive cardiac procedures are expected to drive continued expansion of this segment.

BY APPLICATION

Hospitals

Hospitals remain the primary application segment, accounting for nearly 82% of global transcatheter heart valve procedures. Large hospitals and specialized cardiac centers possess advanced catheterization laboratories, hybrid operating rooms, and multidisciplinary heart teams required to perform complex valve replacement and repair procedures safely and efficiently.

Growing investments in cardiovascular infrastructure, increasing patient volumes, and expanding availability of minimally invasive treatment options continue to reinforce hospital dominance. Comprehensive patient care, advanced imaging technologies, and post-procedure monitoring capabilities make hospitals the preferred setting for transcatheter heart valve interventions.

Ambulatory Surgical Centers

Ambulatory Surgical Centers (ASCs) account for approximately 11% of transcatheter heart valve procedures and are steadily expanding as healthcare systems increasingly emphasize cost-effective outpatient care. These facilities provide shorter hospital stays, lower treatment costs, and improved operational efficiency for carefully selected low-risk patients undergoing minimally invasive cardiac procedures.

Healthcare policy reforms, technological advancements, and improved procedural safety are supporting the gradual expansion of ASCs. Growing patient preference for faster recovery and same-day discharge is encouraging providers to increase the availability of transcatheter interventions in ambulatory settings.

Cardiac Catheterization Laboratory

Cardiac Catheterization Laboratories represent around 7% of total transcatheter heart valve procedures and play a vital role in delivering advanced catheter-based cardiovascular interventions. These facilities provide high-resolution imaging, specialized equipment, and experienced interventional cardiology teams required to perform complex structural heart procedures with precision.

Increasing adoption of minimally invasive therapies, ongoing expansion of catheterization laboratory infrastructure, and advancements in imaging technology continue to support this segment. Their ability to reduce procedural complications and improve clinical outcomes makes cardiac catheterization laboratories an essential component of modern structural heart disease treatment.

Which segment is growing faster?

The Transcatheter Aortic Valve Replacement (TAVR) segment is growing faster due to its widespread adoption for treating severe aortic stenosis, particularly among elderly and high-risk patients. Continuous improvements in valve technology, expanding clinical evidence, and broader physician acceptance have strengthened its position as the leading minimally invasive valve replacement procedure. Increasing use of valve-in-valve procedures and expanded treatment eligibility continue to support the rapid growth of the TAVR segment.

Transcatheter Heart Valve Replacement and Repair Market Regional Outlook

The Transcatheter Heart Valve Replacement and Repair Market shows varied regional performance influenced by patient demographics, healthcare infrastructure, and clinical adoption. North America leads with 37% share, supported by the USA’s high procedural volume. Europe follows with 32%, dominated by Germany, France, and the UK, reflecting advanced healthcare frameworks. Asia-Pacific holds 25% share, with China and India rapidly expanding due to a rising patient base and improved access to cardiac care. The Middle East & Africa account for 6% share, driven by Saudi Arabia, South Africa, and the UAE. Regional differences highlight diverse growth trajectories worldwide.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America is the leading regional market for transcatheter heart valve replacement and repair, accounting for approximately 37% of global procedures. The region benefits from advanced cardiovascular healthcare infrastructure, widespread availability of specialized cardiac centers, and strong adoption of minimally invasive valve replacement and repair technologies. Transcatheter aortic valve replacement remains the most commonly performed procedure, supported by an aging population and increasing prevalence of structural heart diseases.

Continuous technological innovation, favorable reimbursement policies, and the rapid adoption of next-generation transcatheter devices continue to strengthen market growth. Hospitals across the region are increasingly utilizing advanced self-expanding valves and minimally invasive techniques to improve patient outcomes, reduce complications, and shorten recovery times for elderly and high-risk patients.

EUROPE

Europe accounts for nearly 32% of the global transcatheter heart valve replacement and repair market, supported by well-established healthcare systems, extensive clinical expertise, and strong regulatory support for advanced cardiovascular therapies. The region has witnessed widespread adoption of transcatheter procedures across major hospitals, with aortic valve replacement remaining the dominant intervention while mitral valve repair continues to expand steadily.

Growing participation in clinical research, continuous innovation in structural heart technologies, and supportive reimbursement frameworks continue to accelerate market development. Increasing demand from aging populations and broader access to minimally invasive treatment options are encouraging hospitals to expand transcatheter heart valve programs across the region.

ASIA-PACIFIC

Asia-Pacific represents around 25% of the global market and continues to experience rapid growth due to expanding healthcare infrastructure, increasing cardiovascular disease prevalence, and rising investments in advanced cardiac care. The region has significantly increased the number of specialized cardiac centers and catheterization laboratories, improving access to minimally invasive heart valve procedures across both developed and emerging economies.

Government healthcare initiatives, rising healthcare expenditure, and a growing elderly population continue to support market expansion. Increasing awareness among physicians and patients, together with the availability of advanced transcatheter technologies, is accelerating the adoption of valve replacement and repair procedures throughout the region.

MIDDLE EAST & AFRICA

The Middle East & Africa accounts for approximately 6% of the global transcatheter heart valve replacement and repair market. The region is witnessing gradual adoption of minimally invasive cardiac procedures as governments and healthcare providers invest in specialized cardiac centers, modern medical technologies, and improved cardiovascular treatment capabilities.

Growing medical tourism, expansion of tertiary healthcare facilities, and increasing awareness of structural heart disease treatments are contributing to market development. Hospitals remain the primary providers of transcatheter procedures, while continued investments in advanced cardiac infrastructure and physician training are expected to improve patient access to these life-saving interventions across the region.

Which region dominates the Transcatheter Heart Valve Replacement and Repair industry?

North America dominates the Transcatheter Heart Valve Replacement and Repair industry owing to its advanced cardiovascular healthcare infrastructure, high adoption of minimally invasive cardiac procedures, and strong presence of specialized heart centers. Favorable reimbursement policies, continuous technological innovation, and increasing demand from an aging population have accelerated the adoption of transcatheter valve replacement and repair procedures. Ongoing investments in next-generation structural heart technologies continue to reinforce the region's market leadership.

List of Top Transcatheter Heart Valve Replacement and Repair Market Companies

• Abbott
• Abbott Laboratories
• Boston Scientific
• Medtronic
• SYMETIS
• JenaValve Technology
• Edwards LifeSciences
• Braile Biomedica

Top Two companies with highest share

• Edwards LifeSciences: Edwards LifeSciences leads with 19% share, conducting more than 120,000 device implants in 2023, primarily focused on TAVR and TMVR across 60+ countries worldwide.
• Medtronic: Medtronic holds 17% share, delivering over 110,000 transcatheter valve procedures globally in 2023, with strong adoption in both aortic and mitral valve interventions.

Investment Analysis and Opportunities

The Transcatheter Heart Valve Replacement and Repair Market is witnessing robust investments driven by rising cardiovascular disease prevalence and technological innovation. Between 2021 and 2023, more than 450,000 procedures globally were supported by new-generation valves, representing 28% of device investments. North America accounted for 37% of investments, largely in valve-in-valve and self-expanding devices. Europe invested in more than 85 ongoing clinical trials, accounting for 41% of research activity worldwide. Asia-Pacific saw investments in 500+ new cath-labs between 2020 and 2023, supporting expansion in China and India. Opportunities lie in minimally invasive TMVR technologies, which grew 22% from 2020–2023, reflecting demand for alternatives to surgical repair. With over 100 million patients suffering from valvular diseases globally, ongoing investments create strong Transcatheter Heart Valve Replacement and Repair Market Opportunities in device innovation, clinical expansion, and geographic growth.

New Product Development

New product development in the Transcatheter Heart Valve Replacement and Repair Market focuses on durability, minimally invasive features, and expanded indications. In 2023, over 85,000 patients globally were treated with next-generation self-expanding valves, offering 20% fewer complications compared to earlier models. Edwards LifeSciences launched new transcatheter aortic valves with extended durability, addressing long-term treatment for patients under 70 years. Medtronic expanded its TMVR portfolio with devices designed for complex mitral anatomies, improving procedural success rates by 18%. Boston Scientific introduced transcatheter devices with advanced delivery systems, reducing average procedure times by 22%. Additionally, JenaValve Technology’s focus on tricuspid valve systems expanded treatment options for patients with right-sided valve disorders, a segment accounting for 10% of global cases. Innovation continues to drive Transcatheter Heart Valve Replacement and Repair Market Growth by improving patient outcomes and expanding accessibility.

Five Recent Developments 

• In 2023, Edwards LifeSciences launched next-gen self-expanding valves, reducing complication rates by 20% in over 40,000 patients globally.
• In 2024, Medtronic expanded its TMVR portfolio, with more than 18,000 procedures conducted using new devices in Europe and North America.
• In 2024, Boston Scientific introduced delivery systems that cut procedure times by 22% across 12,000 interventions worldwide.
• In 2025, Abbott performed 15,000 tricuspid valve interventions using its investigational devices, addressing right-sided valve disease treatments.
• In 2025, JenaValve Technology expanded tricuspid programs, enrolling 8,000 patients in ongoing multicenter trials globally.

Report Coverage of Transcatheter Heart Valve Replacement and Repair Market

The Transcatheter Heart Valve Replacement and Repair Market Report provides comprehensive insights into global procedures, segmentation, regional adoption, and competitive dynamics. It evaluates more than 680,000 procedures performed worldwide in 2023, including TAVR at 480,000 cases (71% share) and TMVR at 130,000 cases (19% share). By application, hospitals accounted for 560,000 procedures (82%), ambulatory surgical centers 75,000 (11%), and cath-labs 45,000 (7%). Regional analysis highlights North America with 250,000 procedures (37%), Europe with 210,000 (32%), Asia-Pacific with 160,000 (25%), and Middle East & Africa with 40,000 (6%). Competitive insights show Edwards LifeSciences and Medtronic leading with a combined 36% share. The report also details clinical advancements, including valve-in-valve technologies, next-generation devices, and minimally invasive TMVR techniques, all of which are reshaping treatment pathways for over 100 million global patients with valvular heart diseases. This coverage ensures critical Transcatheter Heart Valve Replacement and Repair Market Insights for stakeholders worldwide.

Transcatheter Heart Valve Replacement and Repair Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 15032.64 Million in 2026
Market Size Value By	USD 70162.33 Million by 2035
Growth Rate	CAGR of 18.67% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Transcatheter Aortic Valve Replacement (TAVR) Transcatheter Mitral Valve Repair (TMVR) By Application : Hospitals Ambulatory Surgical Centers Cardiac Catheterization Laboratory
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample